Experts say recent price freezes by pharmaceutical companies are unlikely to result in lower out-of-pocket costs, according to a Time report.
Pfizer, Novartis, Bayer are among the drugmakers who have said they will freeze prices on some of their drugs for the remainder of 2018. Merck & Co. vowed to go one step further and trim the prices on some of its drugs.
Patients, however, will unlikely see any real benefits from the announcements, according to the report.
“It does seem more like a PR type of thing than anything that has a meaningful impact on the patient,” AARP Public Policy Institute Director of Health Services Leigh Purvis tells Time.
